Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Speculative but strong event-driven momentum after FDA agreed on a resubmission path for RP1 plus nivolumab melanoma BLA, with supportive ASCO clinical updates and roughly 132% gain over 20 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Rising Dilution REPL's strong liquidity is outweighed by severe losses, negative free cash flow, rising leverage, and dilution risk, making it a high-risk funding-dependent investment.
Price Behavior
Key Price Behavior Insights: ⢠Upward monthly trend ⢠Recent pullback ⢠Key range breakout Support Level: $14.70â$14.80 Resistance Level: $15.80â$16.00 REPL remains bullish over the last month but is consolidating after a $15.98 peak; hold $14.70â$14.80 support and break $15.80â$16.00 resistance for renewed upside.
Sentiment & News
Key News Insights: ⢠FDA Disclosure Claims ⢠Lead Plaintiff Deadline ⢠Litigation Overhang Replimune faces repeated shareholder-litigation notices alleging inadequate FDA-risk disclosures around RP1, creating continued legal and sentiment pressure.
AI Summary
REPL's FDA-approved TUDRIQEV shifts the thesis from speculative platform biotech to a launch-and-financing execution story, but with heavy cash burn, no reported revenue, and likely dilution, investors should wait for early prescription/reimbursement traction before underwriting expansion upside.
Description
Replimune Group, Inc. is a biotechnology company developing oncolytic immuno-gene therapies for cancer using its proprietary Immunotherapy platform. Its lead candidate, RP1, is a selectively replicating herpes simplex virus 1 therapy being evaluated in clinical trials for solid tumors and cutaneous squamous cell carcinoma, alongside earlier-stage programs including RP2 and RP3. The company was founded in 2015 and is based in Woburn, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 22 | Jun 29 | REPL | Replimune Group, Inc. | Speculative but strong event-driven momentum after FDA agreed on a resubmission path for RP1 plus nivolumab melanoma BLA, with supportive ASCO clinical updates and roughly 132% gain over 20 trading days. | Closed | +0.2% |
| Jun 10 | Jun 17 | REPL | Replimune Group, Inc. | Speculative biotech momentum candidate: stock rose about 113% over 21 trading days, helped by 2026-05-29 FDA alignment on a path forward for RP1 plus nivolumab BLA resubmission/reconsideration and ASCO clinical updates on 2026-05-30 and 2026-05-31. | Closed | +18.1% |